Characterization of the anticancer activity of DW2282, a new anticancer agent

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 5087-5093

  Hwang, Hyun Sook ^a   Moon, Eun Yi ^a   Seong, Seung Kyoo ^a   Choi, Chung Ha ^a   Chung, Yong Ho ^a   Jung, Sang Hun ^b   Lee, Dug Keun ^a   Yoon, Sung June ^a  

^a DongWha Pharm Ind Co   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

Anticancer agent; Apoptosis; Cytotoxicity; DW2282

Indexed keywords

4 PHENYL 1 (4 AMINOBENZOYL)INDOLINE 5 SULFONYL 4,5 DIHYDRO 2 IMIDAZOLONE; ANTINEOPLASTIC AGENT; CYCLOHEXIMIDE; CYTOTOXIC AGENT; DACTINOMYCIN; DEMECOLCINE; DNA FRAGMENT; DW 2282; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL STRAIN K 562; CELL VIABILITY; COLONY FORMING CELL; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; LUNG CARCINOMA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; NEOPLASM PROTEINS; NUCLEIC ACID SYNTHESIS INHIBITORS; PROTEIN SYNTHESIS INHIBITORS; RNA, NEOPLASM; SULFONES; TUMOR CELLS, CULTURED;

EID: 0033395872     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Howbert JJ, Grossman CS, Crowell TA, Rieder BJ, Harper RW, Kramer KE, Tao EV, Aikins J, Poore GA, Rinzel SM, Grindey GB, Shaw WN and Todd GC: Novel agents effective against solid tumors: the diaryl sulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships. J Med Chem 33: 2393-2407, 1990.
2. Jung SH, Song JS, Lee HS, Choi SU and Lee CO, Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones. Arch Pharm Res 19: 570-580, 1996.
3. Jung SH, Lee HS, Yoon SJ, Chung YH, Lee M, Lee DK, Moon EY, Seong SK, and Lee JA, Aryl sulfonyl imidazolone derivatives as an antitumor agent. US patent 08/915,726.
4. Jung SH, Song JS, Lee HS, Choi SU and Lee CO, Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones. Bioorg Med Chem Letters 6: 2553-2558, 1996.
5. Jung SH and Kwak SJ, Planar structural requirement at 4-position of 1-arylsulfonyl-4-phenyl-4, 5-dihydro-2-imidazolones for their cytotoxicity. Arch Pharm Res 20: 283-287, 1997
6. Jung SH, Lee HS, Song JS, Kim HM, Han SB, Lee CW, Lee MS, Choi DR, Lee JA, Chung YH, Yoon SJ, Moon EY, Hwang HS, Seong SK and Lee DK, Synthesis and antitumor activity of 4-phenyl-1-arylsulfonylimidazolidinones. Bioorg Med Chem Letters 8: 1547-1550, 1998.
7. Sun E, Lawrence J, Morre DM, Sun I, Crane F, MacKellar WC and Morre DJ, Proton release from HeLa cells and alkalization of cytoplasm induced by diferric transferrin or ferricyanide and its inhibition by the diarylsulfonylurea antitumor drug N-(4-methyl-phenylsulfonyl)-N′-(4cholorophenyl) urea (LY181984). Biochem Pharm 50: 1461-1468, 1995
8. Kerr JFR and Harmon BV, Apoptosis: Its significance in cancer and cancer therapy. Cancer 73: 2013-2025, 1994.
9. Packham G and Cleveland JL, c-Myc and apoptosis. Biochem Biophys Acta 1242: 11-28, 1995.
10. Lock RB and Stribinskiene L, Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 56; 4006-4012, 1996.
11. Roberge M, Tudan C, Hung SMF, Harder KW, Jirik FR and Anderson H, Antitumor drug Fostriecin inhibits the mitotic entry checkpoint and protein phosphatase 1 and 2A. Cancer Res 54: 6115-6121, 1994.
12. Lock RB, Galpernia OV, Feldhoff RC and Rhodes LJ, Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cslls. Cancer Res 54: 4933-4939, 1994.
13. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A and Boyd MR, Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118, 1990.
14. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A and Boyd MR, Tetrazolium-based assays for cellular viability: A critical examination of selected parameters affecting formazan production. Cancer Res 51: 2515-2520, 1991.
15. Flick DA and Gifford GE, Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Met 68: 167-175, 1984.
16. Bible KC and Kaufmann SH, Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56: 4856-4861, 1996.
17. Matsui S, Arredondo MA, Wrzosek C and Rustum YM, DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res 56: 4715-4723, 1996.
18. Jarvis WD, Turner AJ, Povirk LF, Traylor RS and Grant S, Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 54: 1707-1714, 1994.
19. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C, A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Met 139: 271-279, 1991.
20. Qiao L, Hanif R, Sphicas E, Shiff S and Rigas B, Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol 55: 53-64, 1998.